Search
OT-551
go.drugbank.com/drugs/DB05650InvestigationalOT-551 is a novel small molecule that is topically dosed in an eye drop and has the unique ability to penetrate cell membranes and reach both the front and the back of the eye.
MVA-BN-brachyury-TRICOM vaccine
go.drugbank.com/drugs/DB17424InvestigationalMVA-BN-brachyury-TRICOM vaccine is an investigational cancer vaccine.
Namodenoson
go.drugbank.com/drugs/DB12885InvestigationalNamodenoson has been used in trials studying the treatment of Chronic Hepatitis C and Hepatocellular Carcinoma.
Categories: Purinergic P1 Receptor Agonists105AD7
go.drugbank.com/drugs/DB05113Investigational105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in metastatic colorectal cancer patie...
DPCPX
go.drugbank.com/drugs/DB12946InvestigationalCPX has been used in trials studying the treatment of Cystic Fibrosis.
Categories: Purinergic P1 Receptor AntagonistsFasinumab
go.drugbank.com/drugs/DB12157Investigational[A241190] It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions.
AV-COVID-19
go.drugbank.com/drugs/DB15802InvestigationalAs of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine.
Synonyms: DC-ATABinodenoson
go.drugbank.com/drugs/DB04853InvestigationalBinodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A2A receptor. This specificity allows Binodenoson to deliver - in a single injection - a more effective d...
Categories: Purinergic P1 Receptor AgonistsNV1020
go.drugbank.com/drugs/DB04969InvestigationalNV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.
Dapoxetine
go.drugbank.com/drugs/DB04884InvestigationalDapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latenc...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors